Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
|ClinicalTrials.gov Identifier: NCT01520246|
Recruitment Status : Completed
First Posted : January 27, 2012
Last Update Posted : July 11, 2016
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies gene expression in samples from patients with T-cell acute lymphoblastic leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia Lymphoma||Genetic: gene expression analysis Other: laboratory biomarker analysis|
- To test whether the tumor suppressor candidate gene PDLIM2 is downregulated in human cancers such as T-cell acute lymphoblastic leukemia (T-ALL) and to use the human T-lymphotropic virus 1 (HTLV-1)-mediated in vitro transformation of human T cells as control.
OUTLINE: Previously collected cancer and control tissues are analyzed for the expression patterns of PDLIM2 and other control genes. Human T-cells isolated from human blood are also co-cultured with HTLV-1-transformed T-cell lines.
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Signaling in Tumorigenesis and Immunity|
|Study Start Date :||January 2012|
|Primary Completion Date :||July 2016|
- PDLIM2 expression patterns in cancer and control tissues
- 8-week survival of human T-cell co-cultured with HTLV-1-transformed T-cell lines
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01520246
|Principal Investigator:||Gutian Xiao, MD||University of Pittsburgh|